Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study
出版年份 2019 全文链接
标题
Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study
作者
关键词
Flow cytometry, Hepatocellular carcinoma, Blood, Portal veins, Density gradient centrifugation, Serine proteases, Multivariate analysis, Prognosis
出版物
PLoS One
Volume 14, Issue 5, Pages e0217586
出版商
Public Library of Science (PLoS)
发表日期
2019-05-30
DOI
10.1371/journal.pone.0217586
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prognostic significance of glypican-3 expression in hepatocellular carcinoma
- (2018) Hong Liu et al. MEDICINE
- Preoperative computed tomography and serum α-fetoprotein to predict microvascular invasion in hepatocellular carcinoma
- (2018) Wei Zhang et al. MEDICINE
- Clinicopathological Characteristics of Hepatocellular Carcinoma with Microscopic Portal Venous Invasion and the Role of Anatomical Liver Resection in These Cases
- (2017) Shingo Shimada et al. WORLD JOURNAL OF SURGERY
- Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
- (2017) Johann von Felden et al. Oncotarget
- Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls
- (2015) Robin K Kelley et al. BMC CANCER
- High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers
- (2015) Barry M. Dent et al. INTERNATIONAL JOURNAL OF CANCER
- Individual Profiling of Circulating Tumor Cell Composition and Therapeutic Outcome in Patients with Hepatocellular Carcinoma
- (2014) Ivonne Nel et al. Translational Oncology
- Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma
- (2013) Kornelius Schulze et al. INTERNATIONAL JOURNAL OF CANCER
- Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection
- (2013) Shun-Jun Fu et al. SURGERY
- Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection
- (2012) Yun-Fan Sun et al. HEPATOLOGY
- Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells
- (2011) Sheung Tat Fan et al. ANNALS OF SURGERY
- Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy
- (2011) W. Xu et al. CLINICAL CANCER RESEARCH
- Circulating Epithelial Cells in Patients with Benign Colon Diseases
- (2011) K. Pantel et al. CLINICAL CHEMISTRY
- The Use of Immunohistochemistry in Liver Tumors
- (2010) Elaine S. Chan et al. Clinics in Liver Disease
- Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma
- (2010) Masaki Kaibori et al. JOURNAL OF SURGICAL ONCOLOGY
- Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma
- (2010) Kenji Yorita et al. LIVER INTERNATIONAL
- Predictor for Histological Microvascular Invasion of Hepatocellular Carcinoma: A Lesson from 229 Consecutive Cases of Curative Liver Resection
- (2010) Susumu Eguchi et al. WORLD JOURNAL OF SURGERY
- Microdevice for the isolation and enumeration of cancer cells from blood
- (2009) Swee Jin Tan et al. BIOMEDICAL MICRODEVICES
- Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
- (2009) Hirofumi Shirakawa et al. CANCER SCIENCE
- EpCAM and -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
- (2008) T. Yamashita et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More